Gerresheimer accelerates growth and raises mid term guidance
Gerresheimer is further accelerating its profitable growth following the strategic program of realigning the business with megatrends such as healthcare, sustainability and biotech.
The company has beaten its revenue guidance in 2021. Last year the company generated €1,497 million in core business revenues, achieving a strong organic growth of 7.6%. Core business adjusted EBITDA increased to EUR 324m on a currency-adjusted basis meeting the forecast range.
“2021 was a record year of growth for us. The results show our strategy is paying off: We are turning Gerresheimer into the leading provider of innovative solutions and systems for the healthcare and beauty industry. We continue to invest in key growth areas and these investments are delivering excellent results. We grew High Value Solutions revenues by more than 30%. Biological Solutions increased by more than 40%”, said Dietmar Siemssen, CEO, adding: “We started very strong into FY 2022, making significant progress in profitable, sustainable growth. We confirm for the running financial year to consistently deliver profitable high single-digit revenue growth and we raise our mid-term guidance: We will deliver an adjusted EBITDA margin of 23 to 25% for the Gerresheimer Group.”
The Primary Packaging Glass Division had an organic growth rate of 8.6% in the fourth quarter 2021 due to a strong demand for both tubular and moulded glass.
Clear growth drivers have been again high-value solutions such as biological solutions, ELITE glass and RTF vials as well as the cosmetics business. The Q4 adjusted EBITDA arrived at €43 million.
